Prnewswire·2026-02-25 12:00Core Insights - The full sales and operational launch of Talicia, a leading H. pylori therapy, has commenced under a joint commercialization agreement between Talicia Holdings Inc. and Cumberland Pharmaceuticals, aiming for accelerated market penetration and expanded reach [1][2] - Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based therapy for H. pylori, addressing antibiotic resistance and recommended as a first-line treatment in the 2024 ACG Clinical Guideline [1][2] - H. pylori infection affects approximately 35% of the U.S. adult population, with an estimated 1.6 million patients treated annually, highlighting the significant market potential for Talicia [1][2] Company Overview - RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [2] - The company has entered a co-commercialization agreement with Cumberland Pharmaceuticals to promote Talicia in the U.S. market [1][2] - Talicia received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation and is patent protected until 2042 [1][2] Market Context - H. pylori is classified as a Group 1 carcinogen by the WHO and is a major risk factor for gastric cancer, with approximately 11,000 related deaths in the U.S. annually [1][2] - The increasing antibiotic resistance of H. pylori complicates treatment, with current therapies failing in 25-40% of patients, emphasizing the need for effective solutions like Talicia [1][2] - The company is also exploring potential new market entries in the UK and the Middle East to expand patient access to Talicia globally [1][2]